Preview Mode Links will not work in preview mode

Measure Success Podcast


Apr 27, 2021

Sean McClain is the Founder and CEO of AbSci, a synthetic biology company that uses a patented Protein Printing™ technology to transform traditional biomanufacturing and drug discovery. Sean has spent his career investigating and developing technologies that drive down drug costs, speed up drug development, and enable the manufacture of next-generation biotherapeutics that wouldn’t make it to market otherwise. Under Sean’s leadership, AbSci has grown to more than 100 employees, raised more than $100 million in capital, and has established partnerships with industry-leading pharmaceutical companies to develop biomanufacturing technologies for life-saving drugs.

In 2019, Sean was recognized by Forbes as part of the “30 Under 30 in Science” cohort, and he was named as an “Entrepreneur Of The Year® 2020 Pacific Northwest Region Award Winner.” Sean also serves as a board member for the Oregon Bioscience Association, the Oregon Bioscience Incubator and OTRADI, and Life Science Washington. Sean is a graduate of the University of Arizona, where he studied biochemistry and molecular biology.

In this episode…

Can technology help speed up the process for drug development? How is biomanufacturing hoping to help in the fight against disease? Have you heard of AbSci, the company being heralded as the Google of synthetic biology?

Meet Sean McClain, the Founder and CEO of AbSci and the visionary behind next-generation biotherapeutics. He started his company in 2011 with a determination to question what’s possible and believe in the impossible. Now, Sean’s innovations have him pioneering the way forward and questioning what the future might hold. If you’re curious about the exciting things taking place in the world of biomanufacturing, this episode is for you!

In this episode of the Measure Success Podcast, Carl J. Cox sits down with Sean McClain, Founder and CEO of AbSci, to learn about what’s revolutionizing the field of biomanufacturing. Sean describes how AbSci is speeding up the process of drug development, what he’s doing to keep up with his company’s drastic growth, and why a severe accident inspired him to make some changes. Plus, Sean divulges some of his plans for the future of synthetic biology. Stay tuned!